Regenxbio's RGX-121 gene therapy for Hunter syndrome is the main catalyst, with FDA approval targeted for February 2026.

Axsome Therapeutics, Inc. ( NASDAQ: AXSM) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Good afternoon, everyone, and welcome to Morgan Stanley Global ...

Background: Race is a social construct reflecting broader systemic forces that can affect health, including mental health. We ...

This study illustrates a valuable application of BID-seq to bacterial RNA, allowing transcriptome-wide mapping of pseudouridine modifications across various bacterial species. The evidence presented ...